retatrutide triple agonist gip glp-1 glucagon receptor Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% retatrutide triple agonist gip glp-1

Why does Strive offer multiple concentrations

How JYM L-Carnitine and JYM CLA Work Together Fat utilization depends on two steps: making fatty acids available and then using them for energy

One difference worth noting: short-acting drugs like exenatide maintain their stomach-slowing effects over time, while long-acting drugs like semaglutide tend to show reduced effects after about two weeks , as the body adapts to continuous receptor stimulation

The IATA released its latest financial outlook for the airline industry over the weekend, forecasting a $98 billion jump in the sectors collective fuel bill

Furthermore, Ger et al

May 04, 2025 | 10:10 AM Feedback from our amazing patients